Literature DB >> 27037576

Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model.

E M Moussa1, J Kotarek2,3, J S Blum4, E Marszal2, E M Topp5.   

Abstract

PURPOSE: To investigate in vitro the innate immune response to accelerated stress-induced aggregates of intravenous immunoglobulin (IGIV) using a well-defined human cell-line model, and to correlate the innate response to physical properties of the aggregates.
METHODS: IGIV aggregates were prepared by applying various accelerated stress methods, and particle size, count and structure were characterized. Immune cell activation as tracked by inflammatory cytokines released in response to aggregates was evaluated in vitro using peripheral blood mononuclear cells (PBMC), primary monocytes and immortalized human monocyte-like cell lines.
RESULTS: IGIV aggregates produced by mechanical stress induced higher cytokine release by PBMC and primary monocytes than aggregates formed by other stresses. Results with the monocytic cell line THP-1 paralleled trends in PBMC and primary monocytes. Effects were dose-dependent, enhanced by complement opsonization, and partially inhibited by blocking toll-like receptors (TLR2 and TLR4) and to a lesser extent by blocking Fc gamma receptors (FcγRs).
CONCLUSIONS: Stress-induced IGIV aggregates stimulate a dose-dependent cytokine response in human monocytes and THP-1 cells, mediated in part by TLRs, FcγRs and complement opsonization. THP-1 cells resemble primary monocytes in many respects with regard to tracking the innate response to IgG aggregates. Accordingly, the measurement of inflammatory cytokines released by THP-1 cells provides a readily accessible assay system to screen for the potential innate immunogenicity of IgG aggregates. The results also highlight the role of aggregate structure in interacting with the different receptors mediating innate immunity.

Entities:  

Keywords:  immunogenicity; immunoglobulin; monocytes; protein aggregates

Mesh:

Substances:

Year:  2016        PMID: 27037576     DOI: 10.1007/s11095-016-1914-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  45 in total

Review 1.  The role of the complement system in innate immunity.

Authors:  Horea Rus; Cornelia Cudrici; Florin Niculescu
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Shaken, not stirred: mechanical stress testing of an IgG1 antibody.

Authors:  Sylvia Kiese; Astrid Papppenberger; Wolfgang Friess; Hanns-Christian Mahler
Journal:  J Pharm Sci       Date:  2008-10       Impact factor: 3.534

3.  Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors.

Authors:  Yin Luo; Zhaojiang Lu; Stephen W Raso; Clifford Entrican; Bruce Tangarone
Journal:  MAbs       Date:  2009-09-24       Impact factor: 5.857

4.  Antibody production to aggregated human gamma-G-globulin in acquired hypogammaglobulinemia.

Authors:  C S Henney; E F Ellis
Journal:  N Engl J Med       Date:  1968-05-23       Impact factor: 91.245

5.  Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2011-05-05       Impact factor: 4.200

6.  Amyloid-beta induces chemokine secretion and monocyte migration across a human blood--brain barrier model.

Authors:  M Fiala; L Zhang; X Gan; B Sherry; D Taub; M C Graves; S Hama; D Way; M Weinand; M Witte; D Lorton; Y M Kuo; A E Roher
Journal:  Mol Med       Date:  1998-07       Impact factor: 6.354

7.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

8.  Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics.

Authors:  Vivian Bi; Vibha Jawa; Marisa K Joubert; Arunan Kaliyaperumal; Catherine Eakin; Karen Richmond; Oscar Pan; Jilin Sun; Martha Hokom; Theresa J Goletz; Jette Wypych; Lei Zhou; Bruce A Kerwin; Linda O Narhi; Taruna Arora
Journal:  J Pharm Sci       Date:  2013-08-07       Impact factor: 3.534

9.  Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes.

Authors:  Z D Ling; H J Ziltener; B T Webb; D S Matheson
Journal:  Cell Immunol       Date:  1990-08       Impact factor: 4.868

10.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

View more
  8 in total

Review 1.  Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates.

Authors:  Paul Chamberlain; Bonita Rup
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

2.  Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon beta.

Authors:  Lydia Asrat Haile; Swamy Kumar Polumuri; Roshni Rao; Logan Kelley-Baker; Dimitri Kryndushkin; Rajesh Rajaiah; Tomer Israely; V Ashutosh Rao; Daniela Verthelyi
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

Review 3.  Why the Immune System Should Be Concerned by Nanomaterials?

Authors:  Marc J Pallardy; Isabelle Turbica; Armelle Biola-Vidamment
Journal:  Front Immunol       Date:  2017-05-15       Impact factor: 7.561

4.  Aggregates of IVIG or Avastin, but not HSA, modify the response to model innate immune response modulating impurities.

Authors:  Swamy Kumar Polumuri; Lydia A Haile; Derek D C Ireland; Daniela Verthelyi
Journal:  Sci Rep       Date:  2018-07-31       Impact factor: 4.379

Review 5.  Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates.

Authors:  Myriam Nabhan; Marc Pallardy; Isabelle Turbica
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

6.  Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates.

Authors:  Michael D Swanson; Shantel Rios; Sarita Mittal; George Soder; Vibha Jawa
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

7.  Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: Impact of excipients.

Authors:  Seth G Thacker; Cheng Her; Logan Kelley-Baker; Derek D C Ireland; Mohanraj Manangeeswaran; Eric S Pang; Daniela Verthelyi
Journal:  Front Immunol       Date:  2022-09-06       Impact factor: 8.786

Review 8.  Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.

Authors:  Alison Smith; Hugh Manoli; Stacey Jaw; Kimberley Frutoz; Alan L Epstein; Leslie A Khawli; Frank-Peter Theil
Journal:  J Immunol Res       Date:  2016-08-08       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.